The world’s leading insulin maker, Novo Nordisk, is in for a really “sweet deal” this year after garnering 19.4 billion DKK in net profit for the second quarter of the year

The world’s leading insulin maker, Novo Nordisk, is in for a really “sweet deal” this year after garnering 19.4 billion DKK in net profit for the second quarter of the year, the company unveiled recently. The figure comes in the wake of its popular diabetes drug Ozempic and weight loss drug Wegovy soaring in high demand and worldwide sales. In a press release, CEO Lars Fruergaard Jørgensen said, “We are serving more patients than ever before. The performance in the first six months has enabled us to raise the outlook for the full year.” Following these results, the company now forecasts a 27-33% increase in annual sales, compared with the 24-30% announced in mid-April.